Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aspire Biopharma Holdings ( (ASBP) ) just unveiled an announcement.
On June 10, 2025, Aspire Biopharma Holdings announced the appointment of Michael C. Howe as its new Chief Executive Officer, following Kraig Higginson’s decision to step down from the role. Howe, with extensive experience in leading and building brands in the healthcare and consumer space, is expected to leverage his expertise to drive Aspire’s growth and capitalize on market opportunities. This leadership transition is anticipated to strengthen Aspire’s position in the industry as it prepares for the launch of its innovative pre-workout supplement and continues its clinical trials.
More about Aspire Biopharma Holdings
Aspire Biopharma Holdings, Inc., headquartered in Humacao, Puerto Rico, is a developer of a multi-faceted patent-pending drug delivery technology. The company focuses on creating a novel soluble formulation for rapid and precise delivery of supplements and drugs, utilizing a sublingual delivery method for quick absorption into the bloodstream.
Average Trading Volume: 12,529,533
Technical Sentiment Signal: Sell
Find detailed analytics on ASBP stock on TipRanks’ Stock Analysis page.